Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr-University Bochum, Bad Oeynhausen, Germany.
Department of Cardiology, University of Giessen, Giessen, Germany.
Eur J Cardiothorac Surg. 2018 Mar 1;53(3):552-559. doi: 10.1093/ejcts/ezx408.
Surgical aortic valve replacement (sAVR) is coming under close scrutiny with the recent upswing in the use of less invasive approaches. The aim of this analysis was to identify current trends in patient selection, procedural characteristics and outcomes after sAVR in Germany.
We analysed data from 42 776 patients included in the German Aortic Valve Registry who underwent sAVR with and without coronary artery bypass surgery (CABG) between 2011 and 2015. Baseline, procedural and short-term outcome parameters were analysed.
Of all registered patients, 26 618 (62.2%) underwent isolated sAVR and 16 158 (37.8%) sAVR + CABG. The median age was 72 years, and the median Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) was 2.3%. From 2011 to 2015, there was a decline in STS PROM (2.4-2.2%, P < 0.001) and a decline in risk factors, such as pulmonary hypertension (9.1-3.2%, P < 0.001), occlusive arterial disease (19.6-17.7%, P = 0.003), mitral regurgitation ≥2° (10.6-7.6%, P < 0.001) and New York Heart Association Class III/IV (65.3-59.2%, P < 0.001). In-hospital mortality was 2.3%, 1.3% had disabling stroke, 0.4% residual aortic regurgitation ≥2°, and the incidence of new-onset pacemaker/implantable cardioverter-defibrillator implantation was 3.9%. There was an increase in the use of biological valves in patients <65 years (50.1-65.7%, P < 0.001), and the proportion of rapid deployment valves increased significantly (1.5-8.4%, P < 0.001) over the investigated time period.
Both isolated sAVR as well as sAVR + CABG resulted in excellent in-hospital outcomes based on >42 000 patients treated between 2011 and 2015. The implementation of alternative treatment strategies has resulted in palpable changes in patient and device selection.
随着微创方法应用的日益增多,外科主动脉瓣置换术(sAVR)受到了密切关注。本分析旨在确定德国 sAVR 患者选择、手术特点和短期结局的当前趋势。
我们分析了 2011 年至 2015 年间在德国主动脉瓣登记处接受 sAVR 治疗(伴或不伴冠状动脉旁路移植术 [CABG])的 42776 例患者的数据。分析了基线、手术过程和短期结局参数。
所有登记患者中,26618 例(62.2%)接受了单纯 sAVR,16158 例(37.8%)接受了 sAVR+CABG。中位年龄为 72 岁,中位胸外科医师学会预测死亡率(STS PROM)为 2.3%。2011 年至 2015 年,STS PROM 下降(2.4%-2.2%,P<0.001),肺动脉高压(9.1%-3.2%,P<0.001)、阻塞性动脉疾病(19.6%-17.7%,P=0.003)、二尖瓣反流≥2 度(10.6%-7.6%,P<0.001)和纽约心脏协会心功能分级 III/IV 级(65.3%-59.2%,P<0.001)等危险因素减少。院内死亡率为 2.3%,1.3%发生致残性卒中,0.4%出现残余主动脉瓣反流≥2 度,新发起搏器/植入式心脏复律除颤器植入发生率为 3.9%。65 岁以下患者生物瓣的使用率增加(50.1%-65.7%,P<0.001),快速扩张瓣的比例显著增加(1.5%-8.4%,P<0.001)。
2011 年至 2015 年间,>42000 例患者接受单纯 sAVR 或 sAVR+CABG 治疗,院内结局均极佳。替代治疗策略的实施导致患者和器械选择发生明显变化。